Review article

Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies

Vania Tietsche de Moraes Hungria, Syreeta Allen, Petros Kampanis, Elyara Maria Soares

**Article info**

Article history:
Received 8 June 2015
Accepted 18 November 2015
Available online 1 February 2016

Keywords:
Freeelite®
Serum free light chain assay
Total light chain assay
Multiple myeloma

**Abstract**

The diagnosis of Multiple Myeloma is a challenge to the physician due to the non-specific symptoms (anemia, bone pain and recurrent infections) that are commonplace in the elderly population. However, early diagnosis is associated with less severe disease, including fewer patients presenting with acute renal injury, pathological fractures and severe anemia. Since 2006, the serum free light chain test Freelite® has been included alongside standard laboratory tests (serum and urine protein electrophoresis, and serum and urine immunofixation) as an aid in the identification of monoclonal proteins, which are a cornerstone for the diagnosis of Multiple Myeloma. The serum free light chain assay recognizes the light chain component of the immunoglobulin in its free form with high sensitivity. Other assays that measure light chains in the free and intact immunoglobulin forms are sensitive, but unfortunately, due to the nomenclature used, these assays (total light chains) are sometimes used in place of the free light chain assay. This paper reviews the available literature comparing the two assays and tries to clarify hypothetical limitations of the total assay to detect Multiple Myeloma. Furthermore, we elaborate on our study comparing the two assays used in 11 Light Chain Multiple Myeloma patients at presentation and 103 patients taken through the course of their disease. The aim of this article is to provide a clear discrimination between the two assays and to provide information to physicians and laboratory technicians so that they can utilize the International Myeloma Working Group guidelines.

© 2015 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. All rights reserved.

---

* Corresponding author: The Binding Site, Brasil, Av. Paulista, 2444, Cj 18/05, 01310-300 São Paulo, SP, Brazil.
E-mail address: elyara.soares@bindingsite.com.br (E.M. Soares).
http://dx.doi.org/10.1016/j.rbhh.2015.11.003
1516-8484/© 2015 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. All rights reserved.
Introduction

Monoclonal Gammapathies (MGs) include premalignant Monoclonal Gammapathies of Uncertain Significance (MGUS), Smoldering/Indolent Multiple Myeloma and malignant [Solitary Plasmocytoma, Multiple Myeloma (MM), Light Chain Amyloidosis or Waldenström’s Macroglobulinemia (WM)] conditions. These disorders are commonly characterized by the production of monoclonal proteins which may be either intact immunoglobulins (M-1g), serum free light chains (sFLC), a combination of both, or rarely, free heavy chains only. A percentage of these disorders present without the production of any monoclonal protein.

The asymptomatic disorders are identified through routine laboratory investigations, whilst the diagnosis of the symptomatic disorders can present considerable difficulties to the physician as the symptoms (anemia, recurrent infections, fatigue and bone pain) are common in elderly populations and are not specific to the disease. However, there is a need for timely diagnosis as delays can lead to an increased severity of the disease, including acute renal failure and pathological fractures, which can result in a shorter overall survival.

Immunoglobulin structure and sequence variation

Immunoglobulins are the soluble, secreted form of the B-cell receptor and are composed of repeating mirror images comprising two identical heavy chains (gamma – γ, alpha – α, mu – μ, delta – δ or epsilon – ε) and two identical light chains (kappa – κ or lambda – λ). Immunoglobulin heavy and light chains each have constant and variable regions. A pair of heavy and light chain variable regions together forms the antigen-binding site. The variable regions exhibit enormous structural diversity, particularly of antigen-binding contacts, allowing the recognition of a huge variety of antigens.

In humans, it is calculated that there are at least 10^{11} possible antibody structural variants, which allows for the recognition of a vast number of different antigens. The diversity is generated in four main ways.

Firstly, different combinations of gene segments are used in the rearrangement of heavy and light chain genes during early B-cell development. Kappa light chains are constructed from one of approximately 40 functional variable (V_{\kappa}) gene segments, one of 5 joining (J_{\kappa}) gene segments and a single constant (C_{\kappa}) gene. Lambda light chains are constructed from one of approximately 30 variable (V_{\lambda}) gene segments, and one of four (or more) pairs of functional joining (J_{\lambda}) gene segments and constant (C_{\lambda}) genes. The heavy chain variable region is formed from one of around 60 variable (V_{\text{H}}), one of 30 diversity (D_{\text{H}}), and one of six joining (J_{\text{H}}) gene segments. This combinatorial diversity accounts for a substantial amount of variable region diversity. Secondly, diversity arises from the addition or removal of nucleotides at the junctions between V (D) and J gene segments during recombination. A third source of diversity arises from the many different combinations of heavy and light chains, and finally, somatic hypermutation introduces point mutations in the variable region genes of light and heavy chains in mature activated B-cells.

In light chains, variations are also found in a region of the variable domain corresponding to the first 23 amino acids of the first framework region (a region not associated with antigen binding). Using monoclonal antibodies, four κ (V_{\kappa} – I – V_{\kappa} IV) and six λ subgroups (V_{\lambda} I – VI) have been identified. Such diversity is best identified using polyclonal antibodies that can recognize an extensive range of different epitopes.

Introduction to Freelite®

Freelite® (The Binding Site, UK) is the only nephelometric/turbidimetric assay cleared by the Food and Drug Administration (FDA) of the United States of America for the measurement of serum FLC (sFLC). It uses polyclonal antibodies produced in sheep that specifically recognize and quantify the kappa (κ) and lambda (λ) sFLCs separately, enabling calculation of the kappa/lambda sFLC ratio (rFLC) which can be used to determine clonality. The antibodies specifically recognize epitopes present in the constant region of the light chains, which are hidden when joined to a heavy chain partner (i.e. in the form of the intact immunoglobulin) but are exposed when the light chains are in their free form (Figure 1). The sensitivity of assays has allowed quantification of normal circulating sFLC concentrations for the first time (Reference intervals: κ – median 7.3 mg/L (95th percentile: 3.3–19.4 mg/L); λ – median 12.4 mg/L (95th percentile: 5.7–26.3 mg/L); rFLC is 0.26–1.65). The majority of results of plasma cell dyscrasias show increased production of either the κ or λ sFLC. Individuals who have rFLC values >1.65 may have a monoclonal κ sFLC and those with rFLC values <0.26 may have a monoclonal λ FLC. The applicability of the rFLC in the clinical practice has been proven by a number of scientific publications which led to its inclusion in different international guidelines.

Figure 1 – A diagram of intact immunoglobulin showing the structure of the heavy and light chains. Diagram of the kappa (κ) and lambda (λ) free light chains (FLC) showing the different domains of the light chains and the antibody target that are recognized by the serum free light chain assay.
Current techniques used for the detection of monoclonal proteins

Serum protein electrophoresis (SPEP) is routinely used to identify and quantify intact M-Ig, with immunofixation used to classify according to the heavy chain (γ, α, µ, δ and ε) and light chain (κ or λ) isotypes.\(^6\) Whilst this technique is adequate for most, grossly elevated intact M-Igs, sensitivity can be limited due to co-migration and at low serum concentrations. Furthermore, SPEP poorly identifies sFLC\(^14\) meaning the assay is inadequate for the detection and quantitation of paraproteins produced in light chain MM or Amyloidosis.\(^15\) Historically, 24-hour urine collection has been recommended for the detection of immunoglobulin free light chains, however there is often poor compliance\(^16–18\) and renal function can heavily influence the accuracy of the results.\(^19\)

Differences between free light chain and total light chain assays (hypothetical)

The use of the Freelite assays in the diagnosis of MGs has been well established.\(^13\) However there is often confusion between Freelite and similarly named assays which determine the total light chain concentration in serum and urine. The total light chain assay measures the concentration of all antibodies and free light chains of a particular light chain class i.e. IgG-κ + IgA-κ + IgM-κ + IgD-κ + IgE-κ + free κ. Freelite measures only the free form of the light chain (free κ in our example – Figure 2). Due to the difference in specificity of the assays, total light chain assays identify the light chain component of intact immunoglobulins and free light chains in serum whereas Freelite recognizes only the free light chain component. Therefore, there is a large difference in sensitivity (Table 1) between the two assays. The presence of a polyclonal background prevents the total immunoglobulin assay from being able to distinguish clonality at <4 g/L, whereas the Freelite assay can detect clonality at mg/L concentrations.

Differences between the Freelite and total light chain assays (data)

Recently, Hungria et al.\(^20\) published a study comparing the sensitivity of the sFLC assays to the total light chain assays for samples obtained from 114 light chain MM (LCMM) patients taken through the course of their disease. In keeping with previous reports\(^15,19,21–34\) the FLC identified clonality in 11/11 samples at presentation and identified persistent disease in 80/103 samples taken throughout the course of the disease. In contrast, the total light chain assay identified only 2/11 samples at presentation and 25/103 samples taken throughout the course of the disease. Somewhat confusingly, the light chain isotype was misreported in 11 samples as the opposite light chain.

The International Myeloma Working Group (IMWG) guidelines for the identification of monoclonal immunoglobulins at presentation recommend an algorithm of Freelite + SPEP (Table 2). Hungria et al. showed that, in this study, 11/11 patients were identified using the Freelite assay and there was no need for SPEP. In contrast, total light chain + SPEP identified only 8/11 samples, clearly highlighting the lack of sensitivity of this algorithm recommended by the IMWG guidelines (Figure 3).

The sensitivity of total κ/λ and sFLC assays were compared in a study by Marien et al.\(^35\) Sixteen serum samples from LCMM patients were investigated. Total κ and λ concentrations were measured using Beckman-Coulter reagents on the IMMAGE\(^\text{®}\) nephelometer and sFLC concentrations were measured by Freelite assays (The Binding Site). All samples were abnormal by sFLC assays compared to only five of the 16 samples by total κ and λ assays. In addition, one λ patient was mistyped as κ by the total light chain assay. Other studies have confirmed that total light chain assays are less sensitive than sFLC analysis for the diagnosis of LCMM, Non-secretory MM and Amyloidosis.\(^36–38\)

Summary of the importance of the serum free light chain assay screening

The IMWG concluded that, for the purpose of screening for all MGs (with the exception of Amyloidosis), Freelite can replace 24-hour urine assessments.\(^13\) Furthermore, Katzmann et al.\(^39\) concluded that Freelite costs approximately half as much as 24-hour urine assessment based upon Medicare, USA 2006 reimbursement values.

Recently the IMWG updated the definition of MM to include additional, validated biomarkers alongside CRAB (hypercalcemia, renal failure, anemia, and bone lesions) assessments. A rFLC ≥100, with an involved free light chain concentration of >100 mg/L was included in this validated biomarker list.\(^40\)
Table 1 – Reference intervals and lower limits of sensitivity of free light chain assays and total light chain assays in serum.

| Parameter                        | Kappa reference interval (mg/L) | Kappa sensitivity (mg/L) | Lambda reference interval (mg/L) | Lambda sensitivity (mg/L) |
|----------------------------------|----------------------------------|--------------------------|----------------------------------|---------------------------|
| Free light chains (The Binding Site) | 3.3–19.4                        | 0.3                      | 5.7–26.3                        | 0.4                       |
| Total light chains (Beckman Coulter) | 6290–13500                       | 111                      | 3130–7230                       | 300                       |
| Total light chains (Roche)       | 1380–3750                        | 300                      | 930–2420                        | 300                       |

Figure 3 – Scatter charts showing the differences in sensitivity between the Freelite® and total light chain assays for light chain myeloma patients taken at presentation (n = 11) and through the course of their disease (n = 103) compared to a 100 percentile normal range indicated by parallel lines. FLC: free light chain; SPE: serum protein electrophoresis; PPV: positive predictive value; NPV: negative predictive value.
Table 2 - International Myeloma Working Group recommendations.

|                      | Intact MM | Light chain only MM | Non-secretory MM | AL Amyloidosis |
|----------------------|-----------|---------------------|------------------|----------------|
| Screening            | ✔         |                     |                  |                |
|                      | + serum electrophoresis |                   |                  |                |
| Prognosis            |           |                     |                  |                |
|                      |           | (Oligosecretory)    |                  |                |
|                      |           | (LCE)               |                  |                |

MM: Multiple Myeloma; sIFE: serum immunofixation; uIFE: urine immunofixation; LCE: light chain escape; sFLCs: Serum free light chains.

Hematological response

International guidelines have included Freelite assessments as the most effective monitoring tool in patients with Amyloidosis. More recently, new response criteria were defined based upon changes in Freelite values during treatment. The response criteria utilized the rFLC and the difference between involved and uninvolved free light chains (dFLC); importantly the depth of the assigned response correlated to overall survival.

The IMWG recommend Freelite as the only available and reliable method for the determination of response in patients with Non-secretory and Oligosecretory MM. More recently in LCMM, comparisons of response assessment as determined by 24-hour urine evaluation and Freelite have suggested that Freelite is far superior to the 24-hour urine exam as a tool to measure patient response (Table 2).

In all MM patients, normalization of the Freelite ratio corresponds to superior outcome independently of overall response. The IMWG have refined the definition of complete response, (i) negative immunofixation in serum and urine, (ii) disappearance of plasmacytomas, and (iii) bone marrow infiltration of plasma cells below 5%, to include a normal Freelite ratio. The new response definition, stringent complete response (sCR) relies on a normal Freelite ratio and negative plasma cell evaluation, and corresponds to an improved overall survival.

Conclusions

Early detection of patients with MM is key to a reduction in comorbidities that can impact the quality and duration of life. The sFLC assay, but not the total light chain assay, is an important part of the routine laboratory test algorithm that contributes to the identification of patients with MGs, including MM. To date, there are two pivotal studies that highlight the limited utility of the total light chain assay in the detection of MGs. In the study presented by Hungria et al., the addition of total light chain to SPEP failed to identify all LCMM patients, highlighting an important insensitivity when utilizing this assay. Similar results were reported by Marien et al. The assays can be easily distinguished based upon their normal ranges and caution is urged to utilize the sFLC assay, but not the total light chain assay for the screening, diagnosis and hematological responses in MGs.

Conflicts of interest

Dr. Vania TM Hungria receives research grants and is a speaker for The Binding Site. The others authors declare no conflicts of interest.

Acknowledgments

The authors are thankful to The Binding Site UK, University of Birmingham, UK and Fundação Hemocentro da Santa Casa de São Paulo, SP for their support.

References

1. Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Am J Hematol. 2014;89(12):1133-40.
2. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33.
3. Bridgen ML, Webber D. Clinical Pathology Rounds: the case of the anaplastic carcinoma that was not – potential problems in the interpretation of monoclonal proteins. Lab Med. 2000;31(12):661-5.
4. van Zaalen HC, Diderich PP, Pegels JG, Ruizveldt de Winter JA. Renal insufficiency due to light chain multiple myeloma. Ned Tijdschr Geneeskd. 2000;144(45):2133-7.
5. Chaves Lameiro P, Lazaro de la Osa J, Gonzalez J. Difficulties identifying a monoclonal component in a Bence-Jones multiple myeloma, a clinical case. Biochim Clin. 2013;37-W249a.
17. Tsakiris DJ, Stel VS, Finne P, Fraser E, Heaf J, de Meester J, et al. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrol Dial Transplant. 2010;25(4):1200–6.

18. Janeway CA Jr, Travers P, Walport M. The generation of diversity in immunoglobulins. Immunobiology: the immune system in health and disease. New York: Garland Science; 2001.

19. Solomon A. Light chains of human immunoglobulins. Methods Enzymol. 1985;116:101–21.

20. Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem. 2009;55(3):499–504.

21. Bakshi NA, Golubranson R, Garstka D, Bradwell AR, Kerken DF. Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing M proteins. Am J Clin Pathol. 2005;124(2):214–8.

22. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48(9):1437–44.

23. Abadie JM, Bankson DD. Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population. Ann Clin Lab Sci. 2006;36(2):157–62.

24. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–24.

25. Katzmann JA, Snyder MR, Rajkumar SV, Kyle RA, Therneau TM, Benson JT, et al. Long-term biologic variation of serum protein electrophoresis: M spike, urinary M spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies. Clin Chem. 2011;57(12):1687–92.

26. Abraham RS, Clark RJ, Bryant SC, Lymp JF, Larson T, Kyle RA, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem. 2002;48(4):655–7.

27. Fidler CJ, Hussein AK, Gandhi N, Karur V, Sharma M, Klump TR, et al. Evaluating trends in diagnostic and prognostic testing for multiple myeloma. Blood. 2011;118:2067.

28. Bubson EJ, Taylor J, Beardmore C, Basu S, Mead G, Lovatt T. Utility of serum free light chain analysis when screening for lymphoproliferative disorders. Lab Med. 2009;40(6):325–9.

29. Beetham R, Wassell J, Wallage MJ, Whiteway AJ, James CA. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies? Ann Clin Biochem. 2007;44 Pt 6:516–22.

30. Nowroussian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuepp P, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res. 2005;11 24 (Pt 1):8706–14.

31. Hungria VT, Kamponis P, Drayson MT, Plant T, Crusoee EQ, Peres AI, et al. Comparison of kappa and lambda Freelite to total kappa and lambda immunoassays for the detection of monoclonal gammopathies, both as standalone tests and alongside serum protein electrophoresis. Blood. 2014;124(21):5705.

32. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2003;361(9356):489–91.

M-protein assays: when and how to measure response? Clin Lymphoma Myeloma. 2009;9 Suppl. 1:S56.

23. van Rhee F, Bolejack V, Hollnig K, Pineda-Roman M, Anaissie E, Epstein J, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110(3):827–32.

24. Kraj M, Kruk B, Poglod R, Szczepinski A. Correlation of serum free light chain quantification with serum and urine immunofixation in monoclonal gammopathies. Haematologica. 2011;96:8681a.

25. Avet Loiseau H, Mirbahai L, Young P, Mathiot C, Attali M, Moreau P, et al. Nephelometric measurements of FLC and xFLC for monitoring light chain multiple myeloma patients. Lymphoma Myeloma. 2011.

26. Avet-Loiseau H, Young P, Mathiot C, Attali M, Harousseau J, Bradwell AR, et al. Nephelometric measurements of FLC and xFLC for monitoring light chain myeloma patients. Haematologica. 2011;96:8053a.

27. Kang SY, Suh JT, Lee HJ, Yoon HJ, Lee WI. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. Ann Hematol. 2005;84(9):588–93.

28. Schneider N, Wyncoll A, Kolb B, Sablon E, Gillery P, Maquart FX. Comparative analysis of immunoglobulin free light chains quantification by Freelite (The Binding Site) and N Latex FLC (Siemens) methods. Ann Biol Clin (Paris). 2013;71(1):13–9.

29. Hutchison CA, Plant T, Drayson M, Cockwell P, Koukourti M, Basnayake K, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol. 2008;9:11.

30. Mösbauer U, Ayuk F, Schieder H, Lioznov M, Zander AR, Kroger N. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after autologous stem cell transplantation. Haematologica. 2007;92(2):275–6.

31. Pihler AP, Gulbrandsen N, Kierulf P, Urdal P. Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population. Clin Chem. 2008;54(11):1823–30.

32. Harding SJ, Mead GP, Bradwell AR, Berard AM. Serum free light chain immunoassay as an adjunct to serum protein electrophoresis and immunofixation electrophoresis in the detection of multiple myeloma and other B-cell malignancies. Clin Chem Lab Med. 2009;47(3):302–4.

33. Giarini MM, Giacone L, Caracciolo D, Bruno B, Falco P, Omedè P, et al. Serum free light chains (SFLC) assay: a suggestive new criteria for evaluating disease response, progression and relapse in plasma-cell disorders (PD) and a prognostic factor in monoclonal gammopathy of undetermined significance (MGUS). Haematologica. 2006;91:PO151a.

34. Wolff F, Thiery C, Willems D. Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy. Clin Biochem. 2007;40(5–6):351–4.

35. Marien G, Oris E, Bradwell AR, Blankaert N, Bossuyt X. Detection of monoclonal proteins in sera by capillary zone electrophoresis and free light chain measurements. Clin Chem. 2002;48(9):1600–1.

36. Cavaletti E, Barchiesi V, Cuomo M, Di Paola F, Morabito F, Cavaletti S. A particular case of lambda chain multiple myeloma. Biochim Clin. 2013;57:428–30.

37. Chen HF, Hou J, Yuan ZG, Wang DX, Fu WJ, Chen YB. Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. 2008;29(2):113–6.
38. Smith LJ, Mead GP, Bradwell AR. Comparative sensitivity of serum and urine assays for free light chains. Clin Chem Lab Med. 2003;41.

39. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem. 2005;51(5):878–81.

40. Rajkumar SV, Dimopolous MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.

41. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol. 2005;79(4):319–28.

42. Bird JM, Cavenagh J, Samson D, Mehta A, Hawkins P, Lachmann H. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol. 2004;125(6):681–700.

43. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–9.

44. Corre J, Dejoie T, Caillon H, Attal M, Avet-Loiseau H, Moreau P. Serum free light chains should be the target of response evaluation in light chain multiple myeloma rather than urines: results from the IFM/DFCI 2009 trial. Blood. 2014;124:180a.

45. Moustafa MA, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, et al. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Leukemia. 2015;29(10):2033–8.

46. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.

47. Kapoor P, Kumar S, Dispenzieri A, Lacy M, Dingli D, Hayman SR, et al. Survival outcomes of patients with multiple myeloma (MM) achieving stringent complete response (sCR) following upfront autologous stem cell transplantation (SCT). J Clin Oncol. 2011;29 Suppl.:8069 [abstract].